We noticed you are on our US page. Want to switch regions? Choose from the options:

  • Healthcare Professionals
  • Latest research
  • Publications
  • Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel

Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.

Written by

Armstrong AJ, Saad F, Phung, Dmuchowski C, Fizazi K, Hirmand M, Forer D, Scher HI, Bono J.